William Blair Estimates Skye Bioscience Q1 Earnings

Skye Bioscience, Inc. (NASDAQ:SKYE) – Investment analysts at William Blair issued their Q1 2026 EPS estimates for shares of Skye Bioscience in a report released on Tuesday, April 15th. William Blair analyst A. Hsieh forecasts that the company will post earnings per share of ($0.33) for the quarter. William Blair has a “Outperform” rating on the stock. The consensus estimate for Skye Bioscience’s current full-year earnings is ($1.04) per share. William Blair also issued estimates for Skye Bioscience’s Q3 2026 earnings at ($0.32) EPS and Q4 2026 earnings at ($0.31) EPS.

Separately, Craig Hallum lowered their price target on Skye Bioscience from $18.00 to $14.00 and set a “buy” rating for the company in a research note on Friday, March 21st. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Skye Bioscience has an average rating of “Buy” and an average price target of $16.60.

Skye Bioscience Stock Down 7.6 %

Shares of Skye Bioscience stock opened at $1.58 on Thursday. Skye Bioscience has a 12 month low of $1.14 and a 12 month high of $17.65. The business has a fifty day simple moving average of $1.72 and a 200 day simple moving average of $2.47. The stock has a market cap of $48.94 million, a PE ratio of -2.19 and a beta of 1.88.

Skye Bioscience (NASDAQ:SKYE) last announced its quarterly earnings data on Thursday, March 20th. The company reported ($0.24) earnings per share for the quarter, topping the consensus estimate of ($0.30) by $0.06. During the same period in the prior year, the firm earned ($0.36) EPS.

Hedge Funds Weigh In On Skye Bioscience

A number of large investors have recently added to or reduced their stakes in SKYE. BNP Paribas Financial Markets grew its holdings in shares of Skye Bioscience by 71.1% during the third quarter. BNP Paribas Financial Markets now owns 47,417 shares of the company’s stock worth $185,000 after buying an additional 19,704 shares in the last quarter. Jane Street Group LLC bought a new position in shares of Skye Bioscience in the 3rd quarter valued at about $48,000. Geode Capital Management LLC increased its position in shares of Skye Bioscience by 4.2% during the 3rd quarter. Geode Capital Management LLC now owns 385,793 shares of the company’s stock worth $1,509,000 after purchasing an additional 15,614 shares during the last quarter. Barclays PLC increased its holdings in Skye Bioscience by 36.7% during the third quarter. Barclays PLC now owns 57,889 shares of the company’s stock worth $226,000 after buying an additional 15,551 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. raised its holdings in shares of Skye Bioscience by 20.7% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 62,363 shares of the company’s stock valued at $176,000 after purchasing an additional 10,707 shares during the period. Institutional investors own 21.09% of the company’s stock.

Skye Bioscience Company Profile

Skye Bioscience, Inc, a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy.